{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T04:04:39Z","timestamp":1743998679356,"version":"3.40.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019696","name":"Universidade do Estado da Bahia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.medcli.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:49:33Z","timestamp":1729039773000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety profiles in the use of immune checkpoint inhibitors by patients with cancer and pre-existing autoimmune diseases"],"prefix":"10.1016","volume":"164","author":[{"given":"J\u00falia de Almeida","family":"Santos Freitas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinho Marques","family":"da Silva Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleverton Kleiton","family":"Freitas de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ney Cristian","family":"Amaral Boa Sorte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresita","family":"Bendicho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u00edbal","family":"de Freitas Santos J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.08.003_bib0160","article-title":"Immunotherapy to treat malignancy in patients with pre-existing autoimmunity","volume":"8","author":"Boland","year":"2020","journal-title":"J Imunother Cancer"},{"key":"10.1016\/j.medcli.2024.08.003_bib0165","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0170","article-title":"The state-of-the-art of immunotherapy in the triple-negative breast cancer treatment: main drugs, combinations, mechanisms of action and future perspectives","volume":"67","author":"Tavares","year":"2021","journal-title":"Rev Bras Cancerol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0175","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","article-title":"Adverse drug reactions","volume":"16","author":"Coleman","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.medcli.2024.08.003_bib0180","doi-asserted-by":"crossref","DOI":"10.1177\/10781552231171881","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: an integrative review","author":"Freitas","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.medcli.2024.08.003_bib0185","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5732\/cjc.014.10122","article-title":"Immune checkpoint inhibitors in clinical trials","volume":"33","author":"Sharon","year":"2014","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.medcli.2024.08.003_bib0190","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"year":"2020","series-title":"Common terminology criteria for adverse events (CTCAE), version 5","key":"10.1016\/j.medcli.2024.08.003_bib0195"},{"key":"10.1016\/j.medcli.2024.08.003_bib0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"16","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2024.08.003_bib0205","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1177\/10781552221123967","article-title":"Inpatient utilization of immune checkpoint inhibitors and clinical outcomes","volume":"29","author":"Wang","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.medcli.2024.08.003_bib0210","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0277-9536(99)00390-1","article-title":"Constructions of masculinity and their influence on men's well-being: a theory of gender and health","volume":"50","author":"Courtenay","year":"2000","journal-title":"Soc Sci Med"},{"year":"2008","series-title":"National policy for comprehensive men's health care (PNAISH): principles and guidelines","key":"10.1016\/j.medcli.2024.08.003_bib0215"},{"key":"10.1016\/j.medcli.2024.08.003_bib0220","first-page":"1","article-title":"Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors","volume":"13","author":"Wainstein","year":"2017","journal-title":"Braz J Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0225","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","article-title":"Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study","volume":"24","author":"Cortellini","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.medcli.2024.08.003_bib0230","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0235","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0240","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.medcli.2024.08.003_bib0245","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.medcli.2024.08.003_bib0255","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0260","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0265","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.08.003_bib0270","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.yfrne.2014.04.004","article-title":"Gender differences in autoimmune disease","volume":"35","author":"Ngo","year":"2014","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0275","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0280","doi-asserted-by":"crossref","first-page":"99336","DOI":"10.18632\/oncotarget.22242","article-title":"The sexist behaviour of immune checkpoint inhibitors in cancer therapy?","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.medcli.2024.08.003_bib0285","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.medcli.2024.08.003_bib0290","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.medcli.2024.08.003_bib0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.08.003_bib0300","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.medcli.2024.08.003_bib0305","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"21","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.medcli.2024.08.003_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","article-title":"Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity","volume":"75","author":"Gutzmer","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532400558X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532400558X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:35:51Z","timestamp":1743986151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577532400558X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S002577532400558X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.08.003","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety profiles in the use of immune checkpoint inhibitors by patients with cancer and pre-existing autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}